Pharmafile Logo

Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Genesis Research Group

Genesis Research Group empowers life science companies to innovate differently by fundamentally transforming the way they engage with research partners. Through the integration of robust stakeholder insights (RPR), data-agnostic expertise,…

View Profile

Havas Life London

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…

View Profile

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…

View Profile

Springer Nature

Did you know that we publish over 3,000 journals, and that over 1,000 of those are clinical science journals? Promote your approved branded drugs and medical devices to our audience…

View Profile

Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual stories and interactive experiences that connect with people.

View Profile

Uniphar

Uniphar Group is a trusted global partner to pharmaceutical, medtech, and supply chain and retail companies, working to improve patient access to medicines around the world.

View Profile

Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that we attend each year.

View Profile

Company Details

New Jersey Headquarters, 24 N. Main St, Pennington, NJ, 08534, USA
855.662.6732

 Latest Content from PMHub 

Lucid Group Names Eric Muller as Chief Executive Officer to Lead Next Phase of Growth

Rick Sannem, outgoing CEO, transitions to Strategic Advisor to the Board

Treating phase 2 study design as a scientific decision is compromising launch performance, warns expert

Press Releases | August 17, 2026 | Nmblr

17th August 2026 – Treating Phase 2 study design solely as a set of scientific decisions, without commercial input, is compromising launch performance, according to Janice MacLennan, founder of Nmblr,...

Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR

Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence...

Why Modern Dermatology Demands Curiosity Over Precision

In the high-stakes world of healthcare research and product development, success has long been measured by rigid definitions of precision and predictable trajectories. However, as Dr. Hawa Dumbuya, Director of...

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

Moving Beyond the Pill: Unlocking Value Through Engaged, Empowered, and Educated Patients

True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.

The Heart of the Matter: Medscape Education’s Cardiology Footprint at ESC 2026

For more than 30 years, Medscape Education has built independent, accredited cardiovascular education designed around one goal: improved patient outcomes. This year at the European Society of Cardiology Congress (ESC...

A seat at the table: what the EU HTA reforms really ask of patient involvement

The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.

What do patient stories actually teach us?

Press Releases | July 21, 2026 | Mednet

How do we translate individual experiences into support that helps others and create support that feels personal but remains relevant to many?

Infographic: Are data blind spots putting your launch at risk?

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize...